/FROM PR NEWSWIRE DALLAS 888-776-3971/
IN HEA MEQ
TO BUSINESS, AND HEALTH EDITORS:
Isis Pharmaceuticals to Present at Leerink Swann's 2012 Global
CARLSBAD, Calif., Feb. 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals,
Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today
announced that management will present a company overview at Leerink
Swann's 2012 Global Healthcare Conference on Wednesday, February 15,
2012 at 2:30 p.m. ET at the Waldorf Astoria in New York City.
A live audio webcast of the presentation will be available on the
"Investors & Media" section of the Company's Web site,
www.isispharm.com. A replay of the presentation will be available on
the Isis Web site within 48 hours and will be archived for a limited
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to
discover and develop novel drugs for its product pipeline and for its
partners. Isis' broad pipeline consists of 26 drugs to treat a wide
variety of diseases with an emphasis on cardiovascular, metabolic,
severe and rare diseases, and cancer. Isis' partner, Genzyme, plans
to commercialize Isis' lead product, mipomersen, following regulatory
approval, which is expected in 2012. Isis' patents provide strong and
extensive protection for its drugs and technology. Additional
information about Isis is available at www.isispharm.com.
SOURCE Isis Pharmaceuticals, Inc.
/CONTACT: Kristina Lemonidis, Director, Corporate Communications, +1-760-603-2490, or Amy Blackley, Ph.D., Assistant Director, Corporate Communications, +1-760-603-2772, both for Isis Pharmaceuticals, Inc.
/Web Site: http://www.isispharm.com
CO: Isis Pharmaceuticals, Inc.
IN: HEA MEQ
-- LA49577 --
0000 02/08/2012 12:00:00 EDT http://www.prnewswire.com